Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;58(3):192-199.
doi: 10.4111/icu.2017.58.3.192. Epub 2017 Apr 11.

Thulium laser vaporesection of the prostate: Can we operate without interrupting oral antiplatelet/anticoagulant therapy?

Tarik Emre Sener  1 , Salvatore Butticè  2 , Luciano Macchione  2 , Christopher Netsch  3 , Yiloren Tanidir  1 , Laurian Dragos  4 , Rosa Pappalardo  2 , Carlo Magno  2
Affiliations

Thulium laser vaporesection of the prostate: Can we operate without interrupting oral antiplatelet/anticoagulant therapy?

Tarik Emre Sener et al. Investig Clin Urol. 2017 May.

Abstract

Purpose: Thulium vaporesection of the prostate (ThuVARP) is a new and safe approach for patients receiving anticoagulant therapy in whom transurethral resection of the prostate (TURP) may possess a high bleeding risk. We aimed to demonstrate the efficacy and safety of ThuVARP in patients receiving oral antiplatelet/anticoagulant (OAP/OAC) therapy.

Materials and methods: A total of 103 patients who underwent ThuVARP between 2011 and 2013 were enrolled in the study. Patients were divided into 2 groups. Group A consisted of 47 patients who underwent low molecular weight heparin (LMWH) bridging and group B consisted of 56 patients who were operated on while receiving OAP/OAC therapy.

Results: The drop in hemoglobin levels in the pre- and postoperative periods was significantly higher in group A than in group B. When subgroups were analyzed, the mean drop in hemoglobin was significantly lower in the warfarin and ticlopidine subgroups of group B than in group A. International Prostate Symptom Scores were significantly lower 3, 12, 18, and 24 months after surgery in group A than in group B. Quality of life scores, maximal flow rate values, and postmicturition residual urine volumes (mL) were similar between the 2 groups. A total of 38 and 41 patients in groups A and B, respectively, had no complications.

Conclusions: Our study showed the safety profile of continuing different OAP/OAC therapies in terms of bleeding problems in patients undergoing ThuVARP. We strongly recommend abandoning LMWH bridging and maintaining the OAP/OAC regimen patients are already receiving.

Keywords: Anticoagulants; Low-molecular-weight heparin; Thulium; Transurethral vaporesection of prostate.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors have nothing to disclose.

Figures

Fig. 1
Fig. 1. The postoperative hemoglobin (Hb) levels (g/dL) of patients and the drop in hemoglobin levels. Group A, patients switched from OAP/OAC to low molecular weight heparin; group B, patients undergoing surgery while on OAC/OAP therapy; OAP/OAC, oral antiplatelet/anticoagulant; ASA, acetyl salicylic acid.
Fig. 2
Fig. 2. International Prostate Symptom Scores (A), postmicturition residual urine (B) volumes (mL), maximal flow rate (C) values, and quality of life (D) scores of patients (mean±standard deviation). Group A, patients switched from OAP/OAC to low molecular weight heparin; group B, patients undergoing surgery while on OAC/OAP therapy; OAP/OAC, oral antiplatelet/anticoagulant; ASA, acetyl salicylic acid.
See this image and copyright information in PMC

References

    1. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006;50:969–979. - PubMed
    1. Macchione L, Mucciardi G, Gali' A, Di Benedetto A, Butticè S, Magno C. Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy. Int Urol Nephrol. 2013;45:1545–1551. - PubMed
    1. Rieken M, Ebinger Mundorff N, Bonkat G, Wyler S, Bachmann A. Complications of laser prostatectomy: a review of recent data. World J Urol. 2010;28:53–62. - PubMed
    1. Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, et al. Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol. 2010;28:45–51. - PubMed
    1. Fu WJ, Zhang X, Yang Y, Hong BF, Gao JP, Cai W, et al. Comparison of 2-microm continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective nonrandomized trial with 1-year follow-up. Urology. 2010;75:194–199. - PubMed

MeSH terms

Substances